Table 3.
FDA approved main agents of immune checkpoint inhibitors (ICIs) for colorectal cancer (CRC).
| Regimen | Target population | FDA approved date | Registration number | Reference |
|---|---|---|---|---|
| PD-1 inhibitor | ||||
| Pembrolizumab | Unresectable or metastatic dMMR and high microsatellite instability (MSI-H) CRC | 23 May 2017 |
NCT01876511 KEYNOTE-164 KEYNOTE-177 (NCT02563002) |
(243–245) |
| Nivolumab | DMMR and MSI-H mCRC | 1 August 2017 | CheckMate 037 CheckMate 066 CheckMate 142 (NCT02060188) |
(246–248) |
| PD-1 + CTLA-4 inhibitor | ||||
| Nivolumab + Ipilimumab | DMMR and MSI-H mCRC | 10 July 2018 | CheckMate 142 | (249–251) |